HIV / AIDS Care in Africa: Achievements and Challenges

Séminaire de Pathologie Infectieuse - 27/02/2003

Click here to start

Table of Contents

HIV / AIDS Care in Africa: Achievements and Challenges

Adults and children estimated to be living with HIV/AIDS as of end 2002

Estimated number of adults and childrennewly infected with HIV during 2002

Estimated adults and child deathsdue to HIV/AIDS during 2002

HIV prevalence in adults in sub-Saharan Africa, 1986-2001

Sub-Saharan Africa

HIV/AIDS:GLOBAL CRISIS

Leading causes of death in Africa, 2001

Impact of HIV on life expectancy in Africa

Prevalence among pregnant women, outside major urban areas, Uganda

Mortality and PI-Containing Regimen Use in HIV-Infected Patients with  CD4 Cells, Jan. 1994-June 1997.

Relative Risks of Active TB

TB is the major cause of death

Tuberculosis and Survival of 312 Individuals with Advanced HIV Disease (CD4+ < 15%)

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.Johnson et al. AIDS 2001;15:2137-2147

Comparison of Timing of ACTG 076 and Short-course Antiretroviral Regimens

Effect of Reduction in HIV-1 RNA Levels inSerodiscordant Ugandan Couples on HIV Transmission

Evaluation of UNAIDS HIV Drug Access Initiative Uganda and Côte d’Ivoire

AIDS Care and Support:Implementation and Accomplishments

Background: Program Evaluation UNAIDS HIV Drug Access InitiativeUganda and Côte d’Ivoire

Characteristics of Patients on Antiretroviral Therapy, UNAIDS/MOH Drug Access InitiativeAugust 1998-July 2000

Kaplan-Meier Survival AnalysisUganda UNAIDS/MOH Drug Access Initiative

Phenotypic ResistanceUganda Drug Access Initiative

Genotypic Markers of Resistance to Nucleoside RTI

UNAIDS/MOH DAI Côte d’Ivoire and Uganda: Summary

Development of Simplified, Standardized Algorithms for Treatment and Monitoring

Scaling Up HAART in SSA: Approved ARVs on WHO’s List

Scaling Up HAART in SSA: Second-Line Regimens

Scaling Up HAART in SSA: Special Considerations

Scaling Up HAART in SSA: Tuberculosis co-infection

Pharmacokinetic Interactions Between EFV and RIF in HIV-Infected Patients with Tuberculosis. Lopez-Cortes, et al. Clin Pharm 2002;41:681-690

Research Priorities in ARV MonitoringEvaluation of Low Cost Diagnostics

Research Priorities for Scaling UpAccess to Antiretroviral Therapy

Main reasons for discontinuation of HAART in naive patients (n=862)

Key Predictors of Successful ARV Programs: Attention to Systems for Delivery of AIDS Care, Not Just AIDS Drugs

Providing ART using TB structures

Author: Jean Nachega

Email: seminf@facm.ucl.ac.be

Home Page: http://www.md.ucl.ac.be/seminfect/resume.htm

Other information:
These slides are for information only. Do not make public use of them without the autorization of their author and of the organisers of the 'Séminaire de Pathologie Infectieuse'. Please, adress your request to <seminf@facm.ucl.ac.be>

Download presentation as PDF file